Previous 10 | Next 10 |
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q3 2020 Earnings Call Nov 5, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q3 2020 Earnings Call Transcript
AtriCure (ATRC): Q3 GAAP EPS of -$0.11 beats by $0.23.Revenue of $54.76M (-3.3% Y/Y) beats by $5.39M.Shares +1.7% AH.Press Release For further details see: AtriCure EPS beats by $0.23, beats on revenue
Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year AtriCure, Inc. ( Nasdaq: ATR...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a con...
Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction consider...
Among other criticisms, Kerrisdale Capital cites valuation as part of its short thesis on Atricure (ATRC), given it's near the "highest valuation in its history."Investors' assumptions on a "widespread adoption" of the Convergent procedure and growth in surgical devices are "misplaced."Shares...
AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedures. The TAM for AtriCure's core surgical ablation products is much smaller than AtriC...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference being held virtually...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory r...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...